Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C, Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N.
Harada S, et al. Among authors: shin c.
Mol Ther. 2022 Feb 2;30(2):534-549. doi: 10.1016/j.ymthe.2021.10.006. Epub 2021 Oct 8.
Mol Ther. 2022.
PMID: 34628050
Free PMC article.